

Neola Medical presenting at Medicon Valley Alliance: Our Journey, Their Future.

Neola Medical AB (publ) will present at the Medicon Valley Alliance (MVA) MedTech Network meeting in Lund the 17th of September 2024 at 15:00 CET (15.00). In the presentation titled "Our Journey, Their Future: Neola Medical's groundbreaking technology for saving lives of preterm born babies" CEO Hanna Sjöström will delve into the pivotal experiences that have propelled the company's success and the strategic approaches taken to navigate and overcome industry challenges.

"MVA has been instrumental in fostering collaboration and innovation within the life science community, and I am honored to share Neola Medical's journey and our team's ability to overcome industry challenges to shape the future of neonatal care.", says CEO Hanna Sjöström

This event offers investors a valuable opportunity to gain insights from real-world examples of how industry challenges have been overcome. It also serves as a platform to network with key players in the MedTech sector and explore avenues for collaboration and growth within this dynamic community.

About Medicon Valley Alliance (MVA)

Medicon Valley Alliance (MVA) is a non-profit organization and the driving force behind Denmark and Sweden's dynamic life science community, powering collaborations in the Medicon Valley life science cluster. With over 300 members, including universities, hospitals, businesses, and regional governments, the Medicon Valley Alliance create valuable connections through events, seminars, and projects that foster innovation and knowledge-sharing. Their mission is to position Medicon Valley as the EU's most competitive life science hub by unlocking synergies that benefit all.

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical presenting at Medicon Valley Alliance: Our Journey, Their Future.](#)